What 11 Analyst Ratings Have To Say About Alpine Immune Sciences
Portfolio Pulse from Benzinga Insights
Analysts have recently evaluated Alpine Immune Sciences (NASDAQ:ALPN), with 11 analysts providing diverse outlooks. The average 12-month price target has increased by 42.11% to $54.0. Key analysts have raised their price targets, reflecting positive sentiment.
May 16, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts have shown increased optimism towards Alpine Immune Sciences, raising the average 12-month price target by 42.11% to $54.0. Key analysts from firms like Leerink Partners, RBC Capital, and Morgan Stanley have raised their price targets, indicating a positive outlook.
The increase in the average 12-month price target by 42.11% and the positive adjustments by key analysts suggest a bullish sentiment towards ALPN. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100